Latigo Biotherapeutics Inc(LTGO) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 4 at 7:30 PM ET (Korea 9/5 08:30)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | - | Insider Own | 58.23% | Shs Outstand | 66.3M | Perf Week | -4.91% |
| Market Cap | 1.46B | Forward P/E | - | EPS next Y | - | Insider Trans | 0.77% | Shs Float | 26.4M | Perf Month | - |
| Enterprise Value | 1.72B | PEG | - | EPS next Q | -0.62 | Inst Own | 15.41% | Short Float | 0.51% | Perf Quarter | - |
| Income | - | P/S | - | EPS this Y | - | Inst Trans | 14.19% | Short Ratio | 0.35 | Perf Half Y | - |
| Sales | - | P/B | - | EPS next 5Y | - | ROA | - | Short Interest | 0.13M | Perf YTD | 9.71% |
| Book/sh | -4.16 | P/C | 26.39 | EPS past 3/5Y | - | ROE | - | 52W High | -11.15% ($25.93) | Perf Year | - |
| Cash/sh | 0.87 | P/FCF | - | Sales past 3/5Y | - | ROIC | - | 52W Low | 33.8% ($17.22) | Perf 3Y | - |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | - | Gross Margin | - | Volatility(W/M) | 10.13% - | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 1.86 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 1.15 | EPS Q/Q | - | Profit Margin | - | RSI (14) | 65.97 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.15 | Sales Q/Q | - | SMA20 | 7.28% ($21.48) | Beta | - | Target Price | $52.25 |
| Payout | - | Debt/Eq | 2.5 | Earnings | 2026/9/3 | SMA50 | 8.06% ($21.32) | Rel Volume | 0.59 | Prev Close | $22.48 |
| Employees | - | LT Debt/Eq | 0.05 | EPS/Sales Surpr. | - | SMA200 | 8.06% ($21.32) | Avg Volume(3M) | 0.38M | Price | $23.04 |
| IPO | 2026/8/7 | Option/Short | No/Yes | Trades | 3011 | Volume | 226,462 | Change | 2.49% |
Company
LTGO is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
💊 A US clinical-stage biotech company developing non-opioid painkiller candidates with low addiction risk. The company is pursuing a development strategy targeting both acute and chronic pain, centered on oral candidates that selectively inhibit sodium ion channels involved in pain signal transmission.
Over the past 1 year, roughly in the middle
11% below its 1-year high.
LTGO earns at a steady pace
Tap to view numbers
The price looks about right
Trading at - times earnings.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Long-term returns are close to the market
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership looks stable
Institutions hold 15.4%.
Tap to view numbers
It ranks #4 in the industry
Based on market cap of $1B.
LTGO $1B PER -
VRTX $138B PER 31.8
REGN $85B PER 20.5
ARGX $65B PER 39.4
FAQ
What kind of company is LTGO?
LTGO belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of LTGO?
The market cap of LTGO is approximately $1.5B, ranking 2,378 within its sector.
What is the 52-week high and low for LTGO?
LTGO has recorded a 52-week high of $25.93 and a low of $17.22.
